3,5-Bicyclic aryl piperidines: A novel class of α4β2 neuronal nicotinic receptor partial agonists for smoking cessation
Graphical abstract
References and notes (51)
- et al.
Neuropharmacology
(2000)et al.Mol. Pharmacol.
(2003) - et al.
Curr. Drug. Targets CNS Neuro. Disord.
(2004) - et al.
Psychopharmacology
(2000) - et al.
Treating tobacco use and dependence: Clinical practice guideline
(2000) Annu. Rev. Med.
(1996)- et al.
Respiration
(2002)et al.Respiration
(2002) Org. Lett.
(2000)et al.Org. Lett.
(2000)- et al.
J. Am. Chem. Soc.
(1941) - Vogel’s Textbook of Practical Organic Chemistry, 5th ed; Wiley: New York, 1989; pp...
- et al.
J. Org. Chem.
(1969)
J. Am. Chem. Soc.
BMJ
Pharmacol. Biochem. Behav.
Nature
Pharmacol. Biochem. Behav.
J. Pharmacol. Exp. Ther.
Science
Nature
Eur. J. Pharmacol.
Pharmacol. Biochem. Behav.
J. Clin. Psychiatry. Monograph.
Addiction
Pharmacol. Biochem. Behav.
J. Nic. Tobacco Res.
J. Neurobiol.
Addiction
Mayo Clin. Proc.
Drugs
Drug Disc. Today
CNS Drugs
J. Theor. Biol.
Bioorg. Med. Chem. Lett.
Cited by (62)
Merging metals and strained intermediates
2022, Chem CatalysisCitation Excerpt :Now, 120 years later, the existence of cyclic alkynes and related species is widely accepted.2–17 The strain associated with these species can be leveraged strategically to access a number of important compounds, including ligands,18 fungicides,19 medicinal agents,20 and natural products.4,5,17,21,22 To pay tribute to key historical advances and highlight two major modes of strained intermediate reactivity, we feature pioneering studies from the 1950s and 1960s.
ADHD symptoms impact smoking outcomes and withdrawal in response to Varenicline treatment for smoking cessation
2017, Drug and Alcohol DependenceCitation Excerpt :Regarding smoking cessation, varenicline is a first-line treatment, with some head-to-head studies suggesting that varenicline may be more effective than other first line medications such as nicotine replacement and bupropion (Aubin et al., 2008; Gonzales et al., 2006; Nides et al., 2006) and others suggesting it is similarly effective to nicotine replacement therapies (Baker et al., 2016). Preclinical studies indicate that varenicline acts as a partial agonist at the α4β2 nicotinic acetylcholine receptor (nAChR), with both agonist and antagonist effects (Coe et al., 2005; Rollema et al., 2007). Varenicline is thought to reduce craving and attenuate withdrawal, restlessness, and negative affect during abstinence, potentially via its antagonist action at α4β2 nAChRs, which play a role in mediating nicotine reinforcement (Aubin et al., 2008; Stapleton et al., 2008).
Nicotine- and cocaine-triggered methamphetamine reinstatement in female and male Sprague-Dawley rats
2017, Pharmacology Biochemistry and BehaviorThe effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in female rats
2016, Behavioural Brain ResearchAgonist and antagonist effects of cytisine in vivo
2015, NeuropharmacologyCitation Excerpt :Taking into account poor plasma protein binding (Rollema et al., 2010) and brain/plasma concentration ratio of about 0.3 (Reavill et al., 1990) and assuming that brain protein binding is not much different from plasma protein binding, one may estimate that behaviorally effective doses of cytisine are associated with free brain concentrations of 0.2–0.8 μM (0.7 μM after oral administration of 10 mg/kg of cytisine; Rollema et al., 2010). Given that cytisine binding Ki for α4β2* nicotinic receptors was reported to be in low nanomolar range (Coe et al., 2005; Rollema et al., 2010), such estimates trigger a question whether effects of cytisine are indeed mediated by α4β2 subunit-containing nicotinic receptors. However, one should note that cytisine is a very weak agonist at α4β2* receptors and, in functional assays, cytisine's potency is in micromolar range (Rollema et al., 2010).
Cytisine-like alkaloids from Ormosia hosiei Hemsl. & E.H. Wilson
2014, Phytochemistry